Cellceutix Chooses Destum Partners To Partner Psoriasis Compound
Cellceutix said that KM-133 is also an attractive compound as it may be eligible for an abridged FDA approval process that would allow the compound to go directly
Amgen has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Repatha (evolocumab) supporting its broader use prior to a first heart attack or stroke.